These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33427377)

  • 1. Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections.
    Ramesh D; Vijayakumar BG; Kannan T
    ChemMedChem; 2021 May; 16(9):1403-1419. PubMed ID: 33427377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.
    Wainberg MA; Brenner BG; Turner D
    Antimicrob Agents Chemother; 2005 May; 49(5):1671-8. PubMed ID: 15855480
    [No Abstract]   [Full Text] [Related]  

  • 3. Rational approaches to resistance: nucleoside analogues.
    Mayers D
    AIDS; 1996 Nov; 10 Suppl 1():S9-13. PubMed ID: 8970670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug clinics. How I treat HIV infections. II. Nucleoside reverse transcriptase inhibitors].
    Moutschen M; Nkoghe D; Léonard P; Demonty J
    Rev Med Liege; 1997 Dec; 52(12):750-2. PubMed ID: 9481171
    [No Abstract]   [Full Text] [Related]  

  • 6. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.
    Cihlar T; Ray AS
    Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm.
    Lange J
    Antivir Ther; 2001; 6 Suppl 3():45-54. PubMed ID: 11678472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
    Jockusch S; Tao C; Li X; Anderson TK; Chien M; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
    Antiviral Res; 2020 Aug; 180():104857. PubMed ID: 32562705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 reverse transcriptase inhibitors.
    El Safadi Y; Vivet-Boudou V; Marquet R
    Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.
    Akanbi MO; Scarsi KK; Taiwo B; Murphy RL
    Expert Opin Pharmacother; 2012 Jan; 13(1):65-79. PubMed ID: 22149368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
    Feng JY; Du Pont V; Babusis D; Gordon CJ; Tchesnokov EP; Perry JK; Duong V; Vijjapurapu A; Zhao X; Chan J; Cohen C; Juneja K; Cihlar T; Götte M; Bilello JP
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
    Delaney WE; Locarnini S; Shaw T
    Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoside and nucleotide reverse transcriptase inhibitors in children.
    Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R
    Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).
    Reynolds C; de Koning CB; Pelly SC; van Otterlo WA; Bode ML
    Chem Soc Rev; 2012 Jul; 41(13):4657-70. PubMed ID: 22618809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside analogues in 2008.
    Warwick Z; Churchill D
    J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
    [No Abstract]   [Full Text] [Related]  

  • 17. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
    Clarke JR; Kaye S; Babiker AG; Hooker MH; Tedder R; Weber JN
    J Virol Methods; 2000 Aug; 88(2):117-24. PubMed ID: 10960699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation methods for nucleoside analogues used for treatment of HIV-1 infection.
    Pereira AS; Tidwell RR
    J Chromatogr B Biomed Sci Appl; 2001 Nov; 764(1-2):327-47. PubMed ID: 11817036
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.